New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
08:04 EDTJAZZJazz Pharmaceuticals and Gentium announce Europcean launch of Defitelio
Jazz Pharmaceuticals and Gentium S.p.A., a Jazz Pharmaceuticals company, announced the commencement of the European commercial launch of Defitelio, the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.1 The companies have launched Defitelio in Germany and Austria and expect to continue the launch in 27 additional European countries on a rolling basis during 2014 and 2015.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
07:10 EDTJAZZJazz Pharmaceuticals price target raised to $210 from $190 at UBS
UBS raised its price target on Jazz Pharmaceuticals to $210 from $190 on expectations for Xyrem sales growth, its lower tax rate and its strong balance sheet. UBS reiterated its Buy rating on Jazz Pharmaceuticals shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use